Related references
Note: Only part of the references are listed.Burden of disease progression in patients with multiple myeloma in the US
May Hagiwara et al.
LEUKEMIA & LYMPHOMA (2020)
Adherence to Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma
Hira Mian et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2020)
A systematic literature review looking for the definition of treatment burden
Ahmed Alsadah et al.
HELIYON (2020)
Healthcare utilization and costs among relapsed or refractory multiple myeloma patients on carfilzomib or pomalidomide as monotherapy or in combination with dexamethasone
May Hagiwara et al.
JOURNAL OF MEDICAL ECONOMICS (2019)
Novel Data Linkages to Characterize Palliative and End-Of-Life Care: Challenges and Considerations
Cara L. McDermott et al.
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2019)
Comparison of Electronic Health Record-Based and Claims-Based Diabetes Care Quality Measures: Causes of Discrepancies
Michael Barton Laws et al.
HEALTH SERVICES RESEARCH (2018)
Treatment Outcomes and Health Care Resource Utilization in Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide-only Maintenance, Any Maintenance, or No Maintenance: Results from the Connect MM Registry
Robert M. Rifkin et al.
CLINICAL THERAPEUTICS (2018)
Impact of psychiatric comorbidities on health care utilization and cost of care in multiple myeloma
Shehzad Niazi et al.
BLOOD ADVANCES (2018)
Taxonomy of the burden of treatment: a multi-country web-based qualitative study of patients with chronic conditions
Viet-Thi Tran et al.
BMC MEDICINE (2015)
Real-world costs of chronic lymphocytic leukaemia in the Netherlands
K. M. Holtzer-Goor et al.
LEUKEMIA RESEARCH (2014)
Health Care Costs and Resource Utilization, Including Patient Burden, Associated With Novel-Agent-Based Treatment Versus Other Therapies for Multiple Myeloma: Findings Using Real-World Claims Data
April Teitelbaum et al.
ONCOLOGIST (2013)
Share Paper
